Written by The Non-Alcoholic Steatohepatitis Biomarkers Market is expanding as healthcare providers and researchers place greater emphasis on early and non-invasive approaches to identifying liver disease. According to Market Research Future, the market was valued at USD 0.15 billion in 2024 and is estimated to reach USD 0.1893 billion in 2025. It is projected to reach approximately USD 1.938 billion by 2035, representing a CAGR of 26.19% during 2025–2035.
The market includes hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and other emerging biomarker categories. Hepatic fibrosis biomarkers currently represent the dominant type, while serum biomarkers are experiencing rapid growth because of increasing interest in non-invasive testing. Pharmaceutical companies and CROs form the leading end-user segment, supported by their extensive involvement in research and clinical development.
Technological progress in genomics, proteomics, metabolomics, and high-throughput screening is creating new possibilities for biomarker discovery. Growing awareness of liver health, investment in healthcare infrastructure, and regulatory developments are also supporting market development. These factors are encouraging research into more accurate tools for disease detection, monitoring, and risk assessment.
Access detailed findings to navigate market complexities:
Orthopedic Prosthetics Market Trends
Global Peptic Ulcer Drugs Market Growth
Monoclonal Antibody Therapy Market Demand